Arthritis drug may mask diabetes, study warns
NCT ID NCT07416656
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether sulfasalazine, a drug for inflammatory arthritis, makes the standard diabetes blood test (HbA1c) falsely low. That could mean diabetes goes undiagnosed or is undertreated in these patients. Researchers will use continuous glucose monitors and fasting blood sugar tests in 75 adults to find out how often this happens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sulfasalazine
- What this could lead to
- If successful, this could lead to better diabetes screening guidelines for people with inflammatory arthritis taking sulfasalazine.
- What could go wrong
- This is a small, observational study (75 people) that only identifies a problem—it does not test a new treatment or solution.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Diagnostic Center
RECRUITINGSilkeborg, Central Jutland, 8600, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Could your bone health decide if a dental implant lasts?
- Can a Bone-Sparing hip implant outperform traditional replacement?
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?